Open an account

CASI Pharmaceuticals

CASIF · NASDAQ

$0.1001+$0.00 (+0.00%)TodayMarket closed ·
Prev close $0.1001

About CASIF

CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing innovative therapeutics and pharmaceutical products. The company is headquartered in Beijing, Beijing and currently employs 233 full-time employees. The company went IPO on 2021-08-23. The Company’s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Company’s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The firm mainly conducts its business in the domestic market.

Employees
233
Headquarters
Beijing, Beijing
Listed
Aug 23, 2021
Sector
Health Care
Industry
Biotechnology
Website
casipharmaceuticals.com

CASIF key statistics

Market cap
2.06M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.34K
Volume
471
Open price
$0.1001
High today
$0.1001
Low today
$0.1001
52 Week high
$1.89
52 Week low
$0.05

CASI Pharmaceuticals (CASIF) at a glance

As of Oct 20, 2026, CASI Pharmaceuticals (CASIF) shares are priced at $0.1001, giving the company a market cap of 2.06M and a price-to-earnings ratio of 0.00.

Volume so far is 471 shares, below the average of 1.34K shares a day.

Over the past year CASI Pharmaceuticals has ranged from $0.05 to $1.89, and now sits 3% of the way up that range.

CASI Pharmaceuticals met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q4 FY25 it reported -$0.80 per share against an estimate of -$0.3708.

CASIF earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 14.6% on average.

  1. Q4 FY23: reported -$0.45 per share against an estimate of -$0.2472
  2. Q1 FY24: reported -$0.71 per share against an estimate of -$0.0515
  3. Q2 FY24: reported -$0.55 per share against an estimate of -$0.6489
  4. Q3 FY24: reported -$0.55 per share against an estimate of -$0.6386
  5. Q1 FY25: reported -$0.69 per share against an estimate of -$0.6283
  6. Q2 FY25: reported -$0.86 per share against an estimate of -$0.4841
  7. Q3 FY25: reported -$0.67 per share against an estimate of -$0.412
  8. Q4 FY25: reported -$0.80 per share against an estimate of -$0.3708

Similar companies

Companies in the same industry as CASI Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.